Review Article
Treatment of Liver Metastases in Patients with Neuroendocrine Tumors of Gastroesophageal and Pancreatic Origin
Table 3
Selected randomized trials of targeted therapy in advanced neuroendocrine tumors.
| | Regimen | No. of patients | Tumor response rates (%) | Median PSF (months) | % of NELM | Author
(yr) |
| | PNET | | | | | | | Sunitinib 37.5 mg po qd | 86 | 9 | 11.4 () | 71 (61/86) | Raymond et al. [35] (2011) | | Placebo (+ best supportive care) | 85 | 0 | 5.5 | 54 (46/85) | | | Everolimus 10 mg po qd | 207 | 5 | 11 () | 92 (190/207) | Yao et al. [36]
(2011) | | Placebo (+ best supportive care) | 203 | 2 | 4.6 | 92 (187/203) | | | Everolimus 10 mg po qd | | | | | | Everolimus 10 mg po qd + Bevacizumab 10 mg/kg
every other week | GALGB 80701 | Ongoing | | | | | Carcinoid | | | | | | | Octreotide LAR | 42 | 2 | 14.3 () | 83 (35/42) | Rinke et al. [29] (2009) | | Placebo | 43 | 2 | 6.0 | 88 (38/43) | | | Everolimus + octreotide LAR | 187 | Radiant-2 accrual completed | Final report pending | | | | Placebo + octreotide LAR | 191 | | | | | | Octreotide + bevacizumab | SWOG S0518 | | | | | | Octreotide + placebo | | | | | |
|
|
